H2-Pharma, LLC announced today that it has acquired the exclusive rights to distribute fifteen (15) products from Mayne Pharma, Inc.
H2-Pharma, LLC announced today that it has acquired the exclusive rights to distribute fifteen (15) products from Mayne Pharma, Inc. In 2015 the combined market for these products was approximately $8.3 million according to IMS Health. H2-Pharma has already launched three (3) of these products and will launch the remaining in its own label by the end of 2016.
Bryce M. Harvey, H2-Pharma’s President, stated, “We are pleased to add these products to our growing portfolio of commercial generic drugs. We continue to pursue opportunities to expand our generic business through strategic product acquisitions and distribution agreements. This transaction resonates with our primary goal at H2-Pharma, which is to bring value to our portfolio as well as to our partners’ product portfolios by utilizing our extensive industry experience and knowledge. Our commitment is and will continue to be to foster innovation within our industry by developing new ideas and programs which will benefit each and every one of our partners.”
About Mayne Pharma
Mayne Pharma is a specialty pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company develops and manufactures branded and generic products globally —either directly or through distribution partners — while applying its drug-delivery expertise for contract development and manufacturing services. Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that have been marketed around the world. For more information, please visit their website at www.maynepharma.com.
About H2-Pharma, LLC
H2-Pharma LLC is a privately-held pharmaceutical company focused on the sales, marketing and development of generic pharmaceuticals. With 45 years in the generics industry, H2-Pharma has the experience and distribution infrastructure to market and distribute products across the spectrum, and do so with a level of personal service that is unmatched in the industry.